Nuclear Fuel Fabrication & Fuel Technology▲
BWX Technologies Targets $5.5B-$6B 2030 Revenue After 27% Pullback
BWX Technologies held an investor day on September 29 where management laid out bullish long-term targets, after the stock fell 27% over the past three months. The company, which holds a virtual monopoly on naval nuclear reactors and fuel components for the U.S. Navy, said its total backlog has doubled to $8.4 billion, roughly nine quarters of contracted run rate, and projected 2026 revenue of $3.8 billion, about 98% of it from core nuclear activities. BWXT is selling a majority stake in its non-core medical isotope unit for up to $800 million while retaining a 20% interest, and is reallocating proceeds into nuclear manufacturing assets, including a 500,000-square-foot footprint expansion through the Precision Components Group acquisition. Its updated 2030 roadmap targets annual revenue of $5.5 billion to $6 billion on low double-digit compound organic growth, with adjusted EBITDA margins expanding from 17.5% to approximately 20% and cumulative free cash flow exceeding $2 billion through the end of the decade. The stock, which peaked above $241 and has traded down into the $130-$140 range, still carries a roughly 36x trailing and 27x forward price-to-earnings multiple, while hedge fund holders rose to 65 in the second quarter from 61 in the prior quarter and short interest sits at 4.42% of the public float.
About megatrends
Defense & Geopolitical Fragmentation › Naval Systems & Shipbuilding ▲Supply
Critical Materials & Supply Chain › Nuclear Fuel Fabrication & Fuel Technology ▲Supply
Energy Transition & Power Demand › Advanced Nuclear — SMR & Microreactor Supply
BWXT · Capital · Positive Investor day lays out bullish 2030 revenue/EBITDA/FCF targets, doubled $8.4B backlog, and a $800M medical-isotope divestiture reallocating proceeds into nuclear manufacturing.